194 related articles for article (PubMed ID: 25056532)
1. Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol.
Bošković M; Vovk T; Koprivšek J; Plesničar BK; Grabnar I
Nutr Neurosci; 2016 May; 19(4):156-61. PubMed ID: 25056532
[TBL] [Abstract][Full Text] [Related]
2. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia.
Mahadik SP; Evans D; Lal H
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Apr; 25(3):463-93. PubMed ID: 11370992
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate.
Bošković M; Grabnar I; Terzič T; Kores Plesničar B; Vovk T
Psychiatry Res; 2013 Dec; 210(3):761-8. PubMed ID: 24041751
[TBL] [Abstract][Full Text] [Related]
5. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia.
Arvindakshan M; Ghate M; Ranjekar PK; Evans DR; Mahadik SP
Schizophr Res; 2003 Aug; 62(3):195-204. PubMed ID: 12837515
[TBL] [Abstract][Full Text] [Related]
6. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia.
Mahadik SP; Pillai A; Joshi S; Foster A
Int Rev Psychiatry; 2006 Apr; 18(2):119-31. PubMed ID: 16777666
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Controlled Clinical Trial Investigating the Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Biomarkers of Oxidative Stress, Inflammation and Pregnancy Outcomes in Gestational Diabetes.
Jamilian M; Hashemi Dizaji S; Bahmani F; Taghizadeh M; Memarzadeh MR; Karamali M; Akbari M; Asemi Z
Can J Diabetes; 2017 Apr; 41(2):143-149. PubMed ID: 27881297
[TBL] [Abstract][Full Text] [Related]
8. The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome.
Rahmani E; Samimi M; Ebrahimi FA; Foroozanfard F; Ahmadi S; Rahimi M; Jamilian M; Aghadavod E; Bahmani F; Taghizadeh M; Memarzadeh MR; Asemi Z
Mol Cell Endocrinol; 2017 Jan; 439():247-255. PubMed ID: 27619403
[TBL] [Abstract][Full Text] [Related]
9. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment.
Evans DR; Parikh VV; Khan MM; Coussons C; Buckley PF; Mahadik SP
Prostaglandins Leukot Essent Fatty Acids; 2003 Dec; 69(6):393-9. PubMed ID: 14623492
[TBL] [Abstract][Full Text] [Related]
10. A randomized-controlled clinical trial investigating the effect of omega-3 fatty acids and vitamin E co-supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes.
Taghizadeh M; Jamilian M; Mazloomi M; Sanami M; Asemi Z
J Clin Lipidol; 2016; 10(2):386-93. PubMed ID: 27055970
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
[TBL] [Abstract][Full Text] [Related]
12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
13. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
Suzuki H; Gen K
Hum Psychopharmacol; 2012 Sep; 27(5):470-5. PubMed ID: 23001955
[TBL] [Abstract][Full Text] [Related]
14. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics.
Khan MM; Evans DR; Gunna V; Scheffer RE; Parikh VV; Mahadik SP
Schizophr Res; 2002 Nov; 58(1):1-10. PubMed ID: 12363384
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement.
Rodrigo R; Korantzopoulos P; Cereceda M; Asenjo R; Zamorano J; Villalabeitia E; Baeza C; Aguayo R; Castillo R; Carrasco R; Gormaz JG
J Am Coll Cardiol; 2013 Oct; 62(16):1457-65. PubMed ID: 23916928
[TBL] [Abstract][Full Text] [Related]
16. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Eklund K; Forsman A
Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
[TBL] [Abstract][Full Text] [Related]
17. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of lead neurotoxicity by supplementation of polyunsaturated fatty acid in Wistar rats.
Singh PK; Nath R; Ahmad MK; Rawat A; Babu S; Dixit RK
Nutr Neurosci; 2016 Nov; 19(9):396-405. PubMed ID: 26005885
[TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.
Bentsen H; Osnes K; Refsum H; Solberg DK; Bøhmer T
Transl Psychiatry; 2013 Dec; 3(12):e335. PubMed ID: 24346133
[TBL] [Abstract][Full Text] [Related]
20. Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E.
Eranti VS; Gangadhar BN; Janakiramaiah N
Psychopharmacology (Berl); 1998 Dec; 140(4):418-20. PubMed ID: 9888616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
